Activation of the Nuclear Factor KappaB Pathway by Astrocyte Elevated Gene-1: Implications for Tumor Progression and Metastasis
Overview
Authors
Affiliations
Astrocyte elevated gene-1 (AEG-1) was initially identified as an HIV-1- and tumor necrosis factor alpha (TNF-alpha)-inducible transcript in primary human fetal astrocytes by a rapid subtraction hybridization approach. Interestingly, AEG-1 expression is elevated in subsets of breast cancer, glioblastoma multiforme and melanoma cells and AEG-1 cooperates with Ha-ras to promote transformation of immortalized melanocytes. Activation of the transcription factor nuclear factor kappaB (NF-kappaB), a TNF-alpha downstream signaling component, is associated with several human illnesses, including cancer, and NF-kappaB controls the expression of multiple genes involved in tumor progression and metastasis. We now document that AEG-1 is a significant positive regulator of NF-kappaB. Enhanced expression of AEG-1 via a replication-incompetent adenovirus (Ad.AEG-1) in HeLa cells markedly increased binding of the transcriptional activator p50/p65 complex of NF-kappaB. The NF-kappaB activation induced by AEG-1 corresponded with degradation of IkappaBalpha and nuclear translocation of p65 that resulted in the induction of NF-kappaB downstream genes. Infection with an adenovirus expressing the mt32IkappaBalpha superrepressor (Ad.IkappaBalpha-mt32), which prevents p65 nuclear translocation, inhibited AEG-1-induced enhanced agar cloning efficiency and increased matrigel invasion of HeLa cells. We also document that TNF-alpha treatment resulted in nuclear translocation of both AEG-1 and p65 wherein these two proteins physically interacted, suggesting a potential mechanism by which AEG-1 could activate NF-kappaB. Our findings suggest that activation of NF-kappaB by AEG-1 could represent a key molecular mechanism by which AEG-1 promotes anchorage-independent growth and invasion, two central features of the neoplastic phenotype.
Hernandez-Cedeno M, Rodriguez-Ulloa A, Ramos Y, Gonzalez L, Serrano-Diaz A, Zettl K Biomedicines. 2025; 12(12.
PMID: 39767648 PMC: 11727316. DOI: 10.3390/biomedicines12122740.
Long A, Xu H, Santich B, Guo H, Hoseini S, de Stanchina E J Hematol Oncol. 2024; 17(1):20.
PMID: 38650005 PMC: 11036555. DOI: 10.1186/s13045-024-01538-5.
Hung S, Gaetani M, Li Y, Tan Z, Zheng X, Zhang R J Pharm Anal. 2024; 14(1):100-114.
PMID: 38352946 PMC: 10859541. DOI: 10.1016/j.jpha.2023.09.005.
Chen H, Zhan M, Zhang Y, Liu J, Wang R, An Y JACS Au. 2024; 4(1):139-149.
PMID: 38274259 PMC: 10806767. DOI: 10.1021/jacsau.3c00573.
Yang L, Yang L, Kong F, Zhang S, Pu P, Li X Sci Rep. 2024; 14(1):1949.
PMID: 38253625 PMC: 10803374. DOI: 10.1038/s41598-024-52403-x.